GlassScriptPhysician profile
Lusi Hart
NPI 1669797163
$15,806.78
in general payments reported to CMS, 2019-2025
30 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,242 · 2022: $4,130 · 2023: $3,643 · 2024: $2,654 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,434.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,859.81 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $2,321.77 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,492.21 | 2021-2025 | Mounjaro, Kisunla, Emgality |
| Abbvie INC. | $1,089.18 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $1,036.50 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $995.79 | 2021-2024 | Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $839.35 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $747.77 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $656.54 | 2021-2023 | Austedo Xr, Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.69 | 2021-2023 | Jardiance |
| Axsome Therapeutics, INC. | $480.80 | 2024-2025 | Auvelity |
| Horizon Therapeutics Plc | $420.53 | 2023 | Uplizna |
| Amgen INC. | $381.56 | 2021-2025 | Uplizna, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.11 | 2021-2024 | Trulance, Xifaxan |
| Abbott Laboratories | $342.87 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $285.43 | 2022-2025 | Veozah |
| Qol Medical, LLC | $171.69 | 2025 | Sucraid |
| Idorsia Pharmaceuticals US INC | $137.55 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Alkermes, INC. | $119.51 | 2024 | Vivitrol |
| Currax Pharmaceuticals LLC | $70.20 | 2021-2025 | Contrave, Onzetra Xsail |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.41 | 2024-2025 | Caplyta |
| Lundbeck LLC | $53.27 | 2021-2024 | Rexulti |
| Pfizer INC. | $46.05 | 2024 | |
| Arbor Pharmaceuticals, INC. | $34.47 | 2021 | |
| Azurity Pharmaceuticals, INC. | $34.03 | 2023 | Horizant |
| Exact Sciences Corporation | $29.61 | 2024 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $26.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.83 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $17.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lusi Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.